Vernalis plc

Vernalis plc is a British company specializing in the development of pharmaceutical products. It is a subsidiary of Ligand Pharmaceuticals, an American company. Vernalis was originally established in 1988 as Vanguard Medica, and it was rebranded as Vernalis in 2002. The company's primary focus is on the development of products for the treatment of neurological disorders and cancer.

History[edit | edit source]

Vernalis plc was founded in 1988 as Vanguard Medica by Dr. Peter Bains. The company initially focused on the development of drugs for migraine and Parkinson's disease. In 2002, the company was rebranded as Vernalis following a merger with British Biotech.

In 2018, Vernalis was acquired by Ligand Pharmaceuticals, an American biopharmaceutical company. Following the acquisition, Vernalis continues to operate as a subsidiary of Ligand, focusing on the discovery and development of novel pharmaceutical products.

Products[edit | edit source]

Vernalis has developed several pharmaceutical products, including Frovatriptan for the treatment of migraine, and Apomorphine for the treatment of Parkinson's disease. The company also has several products in various stages of clinical development, including treatments for cancer, inflammatory diseases, and respiratory diseases.

Research and Development[edit | edit source]

Vernalis's research and development efforts are focused on the discovery and development of novel pharmaceutical products. The company utilizes a range of technologies, including structure-based drug design, to develop its products. Vernalis's research and development activities are primarily conducted at its facilities in the United Kingdom.